CTBP2

Across TCGA pan-cancer cohorts, CTBP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CTBP2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CTBP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CTBP2 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

UCEC, LUAD, and GBM are the cancer types where CTBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	All	0.764	0.978	.006	24	view →
LUAD	DFS	Median	II,III,IV	0.427	0.727	.005	13	view →
GBM	OS	Median	All	0.494	0.280	.005	12	view →
HNSC	OS	Quartile	All	0.775	0.948	.008	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
PDAC	DFS	Median	II,III,IV	0.471	0.264	.013	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CTBP2–UCEC (OS)

Open the UCEC breakdown →